30 results
8-K
EX-99.1
AUTL
Autolus Therapeutics plc
5 Jun 24
Registered Number 11185179 (England & Wales) Annual Report and financial statements for the year ended 31 December 2023 for Autolus Therapeutics plc
4:35pm
and provide innovative options for patients. Obe-cel (AUTO1): Obe-cel (obecabtagene autoleucel) is a CD19-targeting programmed T cell investigational therapy … , specific product candidates, innovative manufacturing processes, and constructs that may be used in future product candidates to improve the ability of our
10-K
2023 FY
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
limitations of current treatments and provide innovative options for patients.
Obe-cel has an optimized engagement of the CD19 target designed … candidates, innovative manufacturing processes, and constructs that may be used in future product candidates to improve the ability of our programmed
8-K
EX-99.1
AUTL
Autolus Therapeutics plc
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am
biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric
6-K
EX-99.3
AUTL
Autolus Therapeutics plc
4 May 23
Index to Condensed Consolidated Financial Statements
4:04pm
on delivering on our obe-cel strategy in order to bring this innovative and potentially transformative treatment to an underserved adult Acute
424B5
AUTL
Autolus Therapeutics plc
9 Dec 22
Prospectus supplement for primary offering
5:40pm
-cel for the treatment of relapsed/refractory adult B-cell ALL and in June 2021, we announced that we received innovative licensing and access pathway … , and have the potential to be truly differentiated assets that could address limitations of current treatments and provide innovative options for patients
424B5
gnfmzds15s25hx3p7t
8 Dec 22
Prospectus supplement for primary offering
4:10pm
6-K
EX-99.2
uzuhk5
4 Aug 22
Index to Condensed Consolidated Financial Statements
4:06pm
6-K
EX-99.3
ag9dwcml
4 Aug 22
Index to Condensed Consolidated Financial Statements
4:06pm
6-K
EX-1
cm103
1 Jul 22
Current report (foreign)
5:15pm
6-K
EX-99.2
ot8c0nwmibwp jmtns3m
5 May 22
Index to Condensed Consolidated Financial Statements
12:00am
6-K
EX-99.4
wv6kvy1i
8 Nov 21
Securities Purchase Agreement
5:28pm
424B5
mqcvstuv9oaavqe8 fd
19 Aug 21
Prospectus supplement for primary offering
4:13pm
F-3
roy hombv
6 Aug 21
Shelf registration (foreign)
2:30pm
6-K
EX-1
skfpo84l
30 Jun 21
Annual Report and Accounts
6:05am
424B5
bhqdoad1 cr
11 Feb 21
Prospectus supplement for primary offering
5:16pm
424B5
o5j7sr lscksdn7wyx
8 Feb 21
Prospectus supplement for primary offering
5:27pm
6-K
EX-1
r8g5bjf
26 May 20
Current report (foreign)
4:31pm